Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Tarsus Pharmaceuticals Inc TARS

Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API... see more

Recent & Breaking News (NDAQ:TARS)

Tarsus Added to NASDAQ Biotechnology Index

GlobeNewswire December 16, 2022

Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease

GlobeNewswire December 15, 2022

Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements

GlobeNewswire November 9, 2022

Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting

GlobeNewswire October 25, 2022

Tarsus Announces Transition Plans for Board of Directors

GlobeNewswire October 11, 2022

Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair

GlobeNewswire October 6, 2022

Tarsus Launches "Look at the Lids" Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis

GlobeNewswire September 29, 2022

Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings

GlobeNewswire September 27, 2022

Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis

GlobeNewswire September 7, 2022

Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements

GlobeNewswire August 11, 2022

Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease

GlobeNewswire August 5, 2022

Certara Appoints Rosemary Crane as New Independent Board Member

GlobeNewswire July 25, 2022

Tarsus to Present at the Jefferies 2022 Healthcare Conference

GlobeNewswire May 27, 2022

Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements

GlobeNewswire May 10, 2022

Tarsus to Present at Bank of America 2022 Healthcare Conference

GlobeNewswire May 6, 2022

Tarsus Presents New Findings from Two Studies Demonstrating the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meeting

GlobeNewswire May 5, 2022

Tarsus Announces Pricing of Upsized $75.6 Million Underwritten Public Offering of Common Stock

GlobeNewswire May 3, 2022

Tarsus Announces Proposed $50 Million Underwritten Public Offering of Shares of its Common Stock

GlobeNewswire May 2, 2022

Tarsus Announces Positive Topline Data from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis, and Expects to File a New Drug Application This Year

GlobeNewswire May 2, 2022

Tarsus to Host Webcast to Review Topline Results from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis

GlobeNewswire April 29, 2022